Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo plus ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC)

Abstract

Background Preliminary data from the ABC (76 pts, med f/u 17mo) and CheckMate 204 (94 pts, med f/u 14mo) trials showed that nivo and nivo+ipi have activity in active melanoma brain metastases, with durable responses in a subset of pts. Here, we report the survival and updated response data from all pts enrolled (Nov 2014-Apr 2017) on the randomised Ph2 ABC trial (NCT02374242) of 3 cohorts of pts with active melanoma brain mets naïve to anti-PD1/PDL1/CTLA4. Methods Pts with asymptomatic brain mets with no prior local brain therapy were randomised to cohort A (nivo 1mg/kg + ipi 3mg/kg, Q3Wx4, then nivo 3mg/kg Q2W) or cohort B (nivo 3mg/kg Q2W). Cohort C (nivo 3mg/kg Q2W) had brain mets i) that..